Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families.  Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.

Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.

Biomatics Capital Partners

Alaska Permanent Fund

ARCH Venture Partners

Flagship Pioneering

Baillie Gifford

F-Prime Capital

Eight Roads Ventures

Denali Therapeutics

The #bloodbrainbarrier protects the brain from toxins, but also prevents medicines from entering the brain. We’ve invented a Transport Vehicle (TV) designed to enable protein-based medicines to be carried across that barrier and delivered throughout the brain via existing biological pathways. This novel brain delivery technology has the potential to address a variety of diseases that cause damage inside the brain, potentially making further medical advancements possible. 
#DefeatDegeneration #BrainAwarenessWeek 

We reported our Q3 financial results and business highlights. Read our press release: https://lnkd.in/gubA5Ck2

#TeamDenali joined the Alzheimer's Association of Northern California & Northern Nevada for the Walk to End Alzheimer's in San Francisco this past weekend. Together with the local community, we've taken steps to increase awareness and support research. Thank you to all who participated in this inspiring annual event!   #Walk2EndAlz #AlzheimersAwareness 
#defeatdegeneration

Over the weekend, Denali team members participated in Project Alive's inaugural Hunter syndrome Family Fair, enjoying a day filled with education, connection and Halloween-themed activities with more than 30 MPS II families from across the country! We extend our gratitude to Project Alive for inviting Denali to be a part of this event and value the opportunity to connect with the community and partake in the festive trick-or-treating fun. 

Our team was delighted to participate in the 37th Annual Family and Scientific Conference organized by the National MPS Society in Bethesda, MD. It was another impactful gathering, uniting a diverse community dedicated to having a positive impact in the lives of individuals with MPS and their families. We are grateful for the collaboration and the chance to highlight Denali's research contributions and efforts to develop potential new treatments in MPS. #MPSFamily2023 #defeatdegeneration 

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Google Tag Manager

HSTS

Google Font API

Google Analytics

Content Delivery Network

Global Site Tag

DoubleClick.Net

Chief Medical Officer

Carole Ho

Legal

Chris Walsh

Chief Scientific Officer, Head of Discovery

Joe Lewcock

VP, Small Molecule CMC

Anantha Sudhakar

Senior Vice President, Development Sciences

Dolo Diaz

Vice President, Intellectual Property & Transactions

Mark Kafka

Vice President and Head of Early Clinical

Matthew Troyer

Director, Biologics CMC Program Leadership

Aaron Chesterman

Director, CMC Program Leader

Aaron Miller

Business Management

Akhil Bhalla

Marc Lavigne

Tom Stocky

Robert Nelsen

Nancy Thornberry

Steve Krognes

Ryan Watts

Chief Medical Officer and Head of Development

Steve Lianoglou

Principal Scientist (Bioinformatics) & Lab Lead

Cindy Dunkle

Chief People Officer

Alexander Schuth

Chief Operating and Financial Officer

Katie Peng

Chief Commercial Officer

Charles Morgan

Head Of Regulatory CMC

West Coast Therapeutics Companies

Health Diagnostics Companies With More Than 50 Employees

United States Public Companies With More Than 10 Employees

Health Diagnostics Companies (Top 10K)

Denali Therapeutics is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development.

Post-IPO Equity - Denali Therapeutics

Series B - Denali Therapeutics

Venture Round - Denali Therapeutics

Series A - Denali Therapeutics

San Francisco

California

United States

North America

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why

Denali Therapeutics reports Q2 EPS (59c), consensus (67c)

Denali Therapeutics management to meet with Oppenheimer

Denali Therapeutics price target raised by $1 at JPMorgan, here's why

Denali Therapeutics Executives Sell Shares

Why Is Denali Therapeutics (DNLI) Up 15.6% Since Last Earnings Report?

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth

FDA picks Denali, Neurogene and more for rare disease program

Denali Therapeutics Announces FDA Has Selected DNL126

A brain-penetrant enzyme replacement treatment for Hunter Syndrome.

An investigational LRRK2 inhibitor treatment aimed at slowing the progression of Parkinson's disease.

An investigational treatment focusing on ALS, aiming to slow disease progression.

A drug candidate targeting RIPK1 for the treatment of Multiple Sclerosis.

A program targeting progranulin for the treatment of Frontotemporal Dementia-Granulin.

A therapeutic candidate for MPS IIIA (Sanfilippo Syndrome) focusing on sulfamidase.

China

Asia

Singapore

India

South Korea

HTML5

Adobe Flash

Adobe Fonts

Amazon EC2

jQuery

Vimeo

Google Fonts

DigiCert

GoDaddy Premium DNS

Biogen is a biopharmaceutical company focused on developing therapies for neurological and neurodegenerative diseases.

Biogen Inc.

Roche is a global healthcare company with a strong presence in the pharmaceutical and diagnostics sectors, including products for neurodegenerative diseases.

Roche Holding AG

Amgen is a multinational biopharmaceutical company known for its focus on developing innovative therapies for serious illnesses, including neurological disorders.

Amgen Inc.

Denali Therapeutics is a clinical-stage biopharmaceutical company dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. The company focuses on developing therapeutics for the treatment of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, and other indications.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

news impact assignment basic	general
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	d4075200
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	e6f6d93b
crunchbase profile	general	Nov 25, 2024 11:37 AM	75b378c1
li profile	general	Feb 7, 2024 6:30 PM	231dc8db
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	e19fa5b7
peers	general	Feb 7, 2024 6:30 PM	5e87d5b9
news basic	general	Dec 4, 2024 2:13 PM	a413e0a2
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:DENALITHERAPEUTICS

Denali Therapeutics Inc

Last Close

24.22

22/11 21:00

Market Cap

3.09B

Beta: -

Volume Today

814.16K

Avg: -